Damora Therapeutics, Inc. is trading 5.4% down at $21.11 amid a broader pullback in high-growth, small-cap biotech names.
- The drop extends a multi-day slide from above $24, with today’s weakness aligning with a risk-off macro backdrop and pressure on growth assets.
- There are no fresh company-specific headlines or SEC filings driving the move, suggesting the price action is sentiment-driven.